The recent development of symptomatic pharmacological treatment for Alzheim
er's disease (AD) and the probable introduction of new therapies in a near
future make the assessment of dementia at its different stages an even grea
ter scientific and public health challenge. Neuropsychological tests, toget
her with clinical data, are at present the only in vivo non-invasive screen
ing and diagnostic tools for AD and related disorders. This chapter reviews
the application to AD of standard batteries and short screening tests. It
also analyzes the tests to be applied to detect and assess the specific def
icits of the disease, and discusses the advantages and flaws of current scr
eening and diagnostic tests of dementia. Emphasis is placed on the need to
devise and use tests developed in a rational manner, with high sensitivity
and specificity, not only in the moderate stages of the disease, but also i
n the very early and even "preclinical" stages, as well as during the late
stages (severe dementia). If is known that neuropsychological tests allow o
ne to determine various patients' profiles. Future research should determin
e the possible predictive value of these profiles. This has important impli
cations for therapeutic trials. The current implicit assumption that all pa
tients with AD tend to evolve and decline in a similar fashion needs to be
critically re-examined. (C) 2001, Editrice Kurtis.